Peer-reviewed veterinary case report
Gemcitabine chemotherapy dosing study in cats with cancer
By Garnett, Crystal L et al.·Published in The Canadian veterinary journal = La revue veterinaire canadienne·2016·William R. Pritchard Veterinary Medical Teaching Hospital (Garnett, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Fixed-dose-rate administration of gemcitabine in cancer-bearing cats: A pilot study.
- Species:
- cat
Plain-English summary
A group of cats with cancer received a chemotherapy drug called gemcitabine to see how different doses affected their treatment. The study found that a fixed dose of 5 mg per minute was the best for keeping the drug at effective levels in their blood without going too high. Cats that received lower doses didn't get enough of the medication, while those on higher doses had too much too quickly. This research is helping to refine how gemcitabine can be safely and effectively used in treating cancer in cats.
People also search for: cat cancer treatment gemcitabine · chemotherapy for cats · side effects of gemcitabine in cats
Abstract
Gemcitabine is an antimetabolite chemotherapy agent with schedule-dependent metabolism and efficacy. The purpose of this study was to identify the fixed-dose-rate (FDR) of gemcitabine administration in cancer-bearing cats that achieved a target plasma concentration (TPC) of 10 to 20 μM. Fifteen client-owned cats received gemcitabine infusions administered at various FDR for 1 to 6 hours. Plasma gemcitabine and dFdU (2',2'-difluorodeoxyuridine), the major gemcitabine metabolite, were quantitated by high performance liquid chromatography. Cats treated with an FDR less than 2.5 mg/mper minute failed to achieve TPC, whereas cats treated with an FDR of 10 mg/mper minute quickly exceeded the target range. An FDR of 5 mg/mper minute provided the longest duration of exposure without exceeding the upper limit of the TPC. Plasma dFdU concentration mirrored plasma gemcitabine concentrations. These data suggest that in order to maintain TPC of gemcitabine in cats the FDR lies between 2.5 and 5 mg/mper minute. A Phase II study to evaluate efficacy and toxicity of this approach is underway.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/27807377/